These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28029509)

  • 1. Renal function and venous thromboembolic diseases.
    Janus N; Mahé I; Launay-Vacher V; Laroche JP; Deray G
    J Mal Vasc; 2016 Dec; 41(6):389-395. PubMed ID: 28029509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications].
    Nou M; Laroche JP
    J Mal Vasc; 2016 May; 41(3):197-204. PubMed ID: 27146099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment.
    Kooiman J; den Exter PL; Cannegieter SC; le Cessie S; del Toro J; Sahuquillo JC; Pedrajas JM; Huisman MV
    J Thromb Haemost; 2013 Nov; 11(11):1968-76. PubMed ID: 24112123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ten questions on venous thromboembolism].
    Giustozzi M; Agnelli G
    G Ital Cardiol (Rome); 2019 Nov; 20(11):611-618. PubMed ID: 31697267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of venous thromboembolic disease in cancer patients].
    Farge-Bancel D; Florea L; Bosquet L; Debourdeau P
    Pathol Biol (Paris); 2008 Jun; 56(4):220-8. PubMed ID: 18394821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Treatment of Venous Thromboembolism in Patients with Cancer.
    Prandoni P
    Adv Exp Med Biol; 2017; 906():123-135. PubMed ID: 27620308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic drugs: part I.
    Gallus AS; Hirsh J
    Drugs; 1976; 12(1):41-68. PubMed ID: 789043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of anticoagulation therapy for venous thromboembolism.
    Bounameaux H; Perrier A
    Hematology Am Soc Hematol Educ Program; 2008; ():252-8. PubMed ID: 19074092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
    Harel Z; Sood MM; Perl J
    Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):183-92. PubMed ID: 25636144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
    Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline update. VTE disease: which agents, and when.
    Holten KB; Merok J
    J Fam Pract; 2009 Mar; 58(3):E1. PubMed ID: 19284934
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.
    Goto S; Haas S; Ageno W; Goldhaber SZ; Turpie AGG; Weitz JI; Angchaisuksiri P; Nielsen JD; Kayani G; Farjat A; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
    JAMA Netw Open; 2020 Oct; 3(10):e2022886. PubMed ID: 33112399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LMWH in cancer patients with renal impairment - better than warfarin?
    Bauersachs RM
    Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thromboembolism and antithrombotic management in pregnancy].
    Pajor A
    Orv Hetil; 2011 May; 152(21):815-21. PubMed ID: 21546339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Venous thromboembolic complications in patients with chronic kidney disease: prevalence and features of drug treatment].
    Dzhioeva ON; Orlova AA; Rogozhkina EA; Drapkina OM
    Ter Arkh; 2022 Jan; 94(1):129-134. PubMed ID: 36286928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism in nonagenarians. Findings from the RIETE Registry.
    Vasco B; Villalba JC; Lopez-Jimenez L; Falga C; Montes J; Trujillo-Santos J; Monreal M;
    Thromb Haemost; 2009 Jun; 101(6):1112-8. PubMed ID: 19492156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.
    Pendleton RC; Rodgers GM; Hull RD
    Clin Chest Med; 2010 Dec; 31(4):691-706. PubMed ID: 21047576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.